To the Editor： A 32-year-old Chinese male patient with 1 week cough and dyspnea on exertion was presented to hospital. He was a metastatic lung adenocarcinoma patient with 3 years treatment history. In October 2012, ...To the Editor： A 32-year-old Chinese male patient with 1 week cough and dyspnea on exertion was presented to hospital. He was a metastatic lung adenocarcinoma patient with 3 years treatment history. In October 2012, the patient complained cough, short of breath, and thoracic computerized axial tomography scan （CAT-scan） revealed left lung hilum mass with the right lung multismall patches or opacities. Core needle biopsy on supraclavicular lymph nodes was performed and diagnosis of Stage IV （T3N3MIa） lung adenocarcinoma was made by radiologist, pathologist, and oncologist.展开更多
To the Editor：In 2017,the Global Initiative for Chronic Obstructive Lung Disease （GOLD） released a total revised document （GOLD 2017）,[1] in which one important change is the ＂ABCD＂classification for the manage...To the Editor：In 2017,the Global Initiative for Chronic Obstructive Lung Disease （GOLD） released a total revised document （GOLD 2017）,[1] in which one important change is the ＂ABCD＂classification for the management of patients with chronic obstructive pulmonary disease （COPD）.The assessment tool of the GOLD 2011 combined the symptomatic assessment with the patient＇s spirometric classification and/or risk of exacerbations,and the revised GOLD 2014[2] added the history of hospitalization due to an exacerbation in the preceding year as a method of assessing exacerbation risk.However,increasing evidence suggested the limitations of the forced expiratory volume in 1 s （FEV1） in influencing prognostic and therapeutic decisions.The new GOLD 2017 classification separates spirometric grades from the ＂ABCD＂groups.[1] To date,the impact of this revision on grouping and subsequent drug selection has been insufficiently studied.展开更多
Lung-related diseases are the third-leading cause of human death throughout the world. Lethal lung diseases such as chronic obstructive pulmonary disease （COPD）, pulmonary fibrosis and bronchiectasis are characteriz...Lung-related diseases are the third-leading cause of human death throughout the world. Lethal lung diseases such as chronic obstructive pulmonary disease （COPD）, pulmonary fibrosis and bronchiectasis are characterized by irreversible, progressive damage of the lung tissue.展开更多
文摘To the Editor： A 32-year-old Chinese male patient with 1 week cough and dyspnea on exertion was presented to hospital. He was a metastatic lung adenocarcinoma patient with 3 years treatment history. In October 2012, the patient complained cough, short of breath, and thoracic computerized axial tomography scan （CAT-scan） revealed left lung hilum mass with the right lung multismall patches or opacities. Core needle biopsy on supraclavicular lymph nodes was performed and diagnosis of Stage IV （T3N3MIa） lung adenocarcinoma was made by radiologist, pathologist, and oncologist.
文摘To the Editor：In 2017,the Global Initiative for Chronic Obstructive Lung Disease （GOLD） released a total revised document （GOLD 2017）,[1] in which one important change is the ＂ABCD＂classification for the management of patients with chronic obstructive pulmonary disease （COPD）.The assessment tool of the GOLD 2011 combined the symptomatic assessment with the patient＇s spirometric classification and/or risk of exacerbations,and the revised GOLD 2014[2] added the history of hospitalization due to an exacerbation in the preceding year as a method of assessing exacerbation risk.However,increasing evidence suggested the limitations of the forced expiratory volume in 1 s （FEV1） in influencing prognostic and therapeutic decisions.The new GOLD 2017 classification separates spirometric grades from the ＂ABCD＂groups.[1] To date,the impact of this revision on grouping and subsequent drug selection has been insufficiently studied.
文摘Lung-related diseases are the third-leading cause of human death throughout the world. Lethal lung diseases such as chronic obstructive pulmonary disease （COPD）, pulmonary fibrosis and bronchiectasis are characterized by irreversible, progressive damage of the lung tissue.
